Determining the level of fibrosis is key in evaluating patients for HBV treatment candidacy. How, when, and why should we incorporate fibrosis assessments into clinical practice? Here’s my take.
How I incorporate family history into HBV treatment and monitoring decisions in certain clinical gray zones.
Why I consider treatment for patients with immune-tolerant chronic HBV, and where I differ from current international guidance.
When managing pregnant patients with chronic HBV, the optimal timing for prophylaxis discontinuation postpartum remains unclear. Here’s my approach.
This concise MedicalMinute presentation reviews the natural history of HBV infection and interpreting serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
This concise MedicalMinute presentation reviews the AASLD guidelines on monitoring and treatment for patients with HBV infection, including a brief discussion of HCC risk in various patient populations.
This concise MedicalMinute presentation reviews the AASLD recommendations on methods to assess liver fibrosis and inflammation and data and guidance on translating test results into management decisions.
This concise MedicalMinute presentation reviews the AASLD recommendations for caring for pregnant women with chronic HBV infection, including considerations for monitoring, treatment indications, treatment options, and prophylaxis to prevent mother-to-child transmission.
In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.
In episode 3 of this ongoing series, listen to a conversation between Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, on incorporating shared decision-making to determine when to initiate treatment.
In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels.
Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.
Review key data and AASLD guideline recommendations on HCC risk, considerations for treatment, and optimal HCC monitoring.
Review key data and AASLD guideline recommendations on methods to evaluate liver fibrosis and inflammation to guide management decisions for patients with HBV infection.
Review key data and AASLD guideline recommendations on managing HBV infection during pregnancy, including treatment indications, treatment options, and prophylaxis to prevent mother-to-child transmission.
Assessment of liver disease severity is often overlooked in the management of patients with HBV infection, but it can tip the scales when weighing the decision to treat or monitor.
Rapid expansion of the use of new immunosuppressive agents and failure to screen patients for HBV prior to therapy initiation can lead to HBV reactivation. Here’s my approach to preventing reactivation.
This concise MedicalMinute presentation reviews the APASL guidelines on treatment indications for patients with HBV infection, including a brief discussion of methods to assess fibrosis.
Listen to expert insights on the limitations of the current APASL recommendations for screening and surveilling patients with chronic hepatitis B for hepatocellular carcinoma.
In episode 1 of this ongoing series, listen to a conversation between Grace LH Wong, MD, and her patient, Ms. Chan, on the shared decision for Ms. Chan to start treatment for hepatitis B infection during her pregnancy.
Review APASL guideline recommendations informing HBV treatment candidacy, including fibrosis assessments and ongoing monitoring.
Here’s why it’s important to look for HDV coinfection in patients with HBV.
The role of host factors in the monitoring and treatment of chronic hepatitis B is an area largely unexplored by the guidelines. Here’s my approach to assessing patients for treatment candidacy in the setting of other host factors.
This concise MedicalMinute presentation reviews the EASL recommendations for the individualizing treatment of HBV infection in persons at risk of renal or bone disease and pregnant women.
Hear expert insights on when to treat HBV: which factors to consider and how often to monitor them.
In episode 4 of this ongoing series, listen to a conversation between Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, and his patient Mark, who presented with hepatitis B after receiving immunomodulatory treatment for rheumatoid arthritis.
Review key data and EASL guideline recommendations on individualizing treatment for patients with HBV, including patients with renal or bone disease and pregnant women.